USPTO serial 97583564
THERAMEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 5, 2023
- Examiner
- BERNS, LEE ANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with THERAMEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Belgravia, London, GB
Belgravia, London, GB
Belgravia, London, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 PENNSYLVANIA AVENUE NW, SUITE 9000WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's health, namely, menopause, osteoporosis, uterine fibroids, endometriosis, adenomyosis, menstrual bleeding disorders, fertility, infertility, assisted reproductive technology, IVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive health, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conception, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injection, osteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 5, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 5, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 21, 2023 | ISPO | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST | — |
| Sep 20, 2023 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Sep 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 14, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 6, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 6, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 6, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 26, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 12, 2022 | NWAP | NEW APPLICATION ENTERED | — |